Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

MedXY Editorial Team•Oct 21, 2025•Neurology

Valiltramiprosate, a potent inhibitor of amyloid-β oligomer formation, was tested in a 78-week phase III trial in APOEε4/ε4 homozygotes with early Alzheimer’s disease (AD).
The overall study population showed significant slowing of hippocampal atrophy but no significant clinical improvement on the primary cognitive endpoint.
Prespecified analyses in the mild cognitive impairment (MCI) subgroup demonstrated nominally significant slowing in cognitive decline and functional measures alongside imaging benefits.
The treatment was generally well tolerated, with mainly gastrointestinal adverse events and no increased risk of amyloid-related imaging abnormalities (ARIA).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Valiltramiprosate, a potent inhibitor of amyloid-β oligomer formation, was tested in a 78-week phase III trial in APOEε4/ε4 homozygotes with early Alzheimer’s disease (AD).
The overall study population showed significant slowing of hippocampal atrophy but no significant clinical improvement on the primary cognitive endpoint.
Prespecified analyses in the mild cognitive impairment (MCI) subgroup demonstrated nominally significant slowing in cognitive decline and functional measures alongside imaging benefits.
The treatment was generally well tolerated, with mainly gastrointestinal adverse events and no increased risk of amyloid-related imaging abnormalities (ARIA).